Key Insights

Highlights

Success Rate

71% trial completion

Published Results

57 trials with published results (28%)

Research Maturity

107 completed trials (52% of total)

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 64/100

Termination Rate

21.0%

43 terminated out of 205 trials

Success Rate

71.3%

-15.2% vs benchmark

Late-Stage Pipeline

12%

24 trials in Phase 3/4

Results Transparency

53%

57 of 107 completed with results

Key Signals

57 with results71% success43 terminated

Data Visualizations

Phase Distribution

184Total
Not Applicable (28)
Early P 1 (3)
P 1 (47)
P 2 (82)
P 3 (21)
P 4 (3)

Trial Status

Completed107
Terminated43
Unknown24
Recruiting11
Withdrawn10
Active Not Recruiting6

Trial Success Rate

71.3%

Benchmark: 86.5%

Based on 107 completed trials

Clinical Trials (205)

Showing 20 of 20 trials
NCT06008808Phase 1Recruiting

Ruxolitinib With and Without CTLA-4 Ig Abatacept for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation

NCT07356245Phase 2Recruiting

Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma

NCT03602599RecruitingPrimary

Chronic Graft-versus-Host Disease in the Oral Cavity of Patients Following Allogeneic Hematopoietic Stem Cell Transplant and Including Healthy Controls

NCT03192397Phase 1Active Not Recruiting

Chemotherapy, Total Body Irradiation, and Post-Transplant Cyclophosphamide in Reducing Rates of Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant

NCT07006506Phase 2RecruitingPrimary

A Study of Belumosudil in People at Risk of Developing Graft-Versus-Host Disease After a Stem Cell Transplant

NCT01453140Phase 1TerminatedPrimary

In-vivo Regulatory T Cell Enhancement With Cyclophosphamide and Sirolimus

NCT06705062Phase 3Recruiting

Study Comparing Reduced Versus Standard Dose Post-transplantation Cyclophosphamide in Combination With Post-engraftment Anti-thymoglobin as Graft Versus Host Disease Prophylaxis in Alternative Donor Peripheral Stem Cell Transplantation

NCT02386800Phase 4Active Not Recruiting

CINC424A2X01B Rollover Protocol

NCT07235501Not Yet RecruitingPrimary

Kinetic Analysis of Immune Cells in Blood and Chronic Graft-Versus-Host Disease-Affected Tissues After Allogeneic Hematopoietic Cell Transplantation

NCT03924401Phase 2Active Not RecruitingPrimary

Acute GVHD Suppression Using Costimulation Blockade to Expand Non-malignant Transplant

NCT04886726Phase 1RecruitingPrimary

PTCY Plus uhCG/EGF for Graft Versus Host Disease Prophylaxis

NCT06252870Phase 2RecruitingPrimary

Study Testing Two Conditioning Regimen With a Single Prophylaxis of GVHD by Cyclophosphamide and Methotrexate Post-transplant in Patients Eligible for Matched-donor Allograft Transplantation

NCT07319000Phase 2CompletedPrimary

Efficacy of Low-dose PT-Cy for Prevention of GVHD in Ambulatory Allogeneic HSCT

NCT04660487RecruitingPrimary

Relationship Between "FODMAPs" and "GVHD"

NCT03983850Phase 1Active Not RecruitingPrimary

Optimizing PTCy Dose and Timing

NCT03438643TerminatedPrimary

Dynamic of Immunocompetent Populations in Patients Treated With Extracorporeal Photopheresis in Chronic Graft Versus Host Disease

NCT02891395Phase 2CompletedPrimary

Efficacy and Safety of Nilotinib in Patients With a Chronic Disease of the Graft Against the Host

NCT03367962Phase 1CompletedPrimary

Detection of Graft Versus Host Disease With [18F]F-AraG

NCT00284986Phase 2CompletedPrimary

Safety and Efficacy of Prochymal for the Salvage of Treatment-Refractory Acute GVHD Participants

NCT05866302Recruiting

Parametric Response Mapping (PRM) for the Detection of Chronic Lung Injury in Hematopoietic Cell Transplant Recipients

Scroll to load more

Research Network

Activity Timeline